PNH Ve aHÜS İle Mücadele Derneği̇n’den Haberler
PNH VE aHÜS İLE MÜCADELE DERNEĞİN’DEN HABERLER Derneğimiz tarafında ilk defa gerçekleştirilen toplantı organizasyonu, İstanbulÜniversitesi Tıp Fakültesi Salonlarında, 15 Şubat 2025…
Pregnancy exposure impact : Eculizumab and Ravulizumab
Recently information about the Ravulizumab Pregnancy Registry was featured on this site. Ever since Ravulizumab was approved the issue of its…
Primary aHUS renaming progress
The renaming of Primary aHUS is inevitable. The experts have said so and the name change creep, albeit unofficial, is gathering…
FDA has a record about aHUS
In 2023 a group from the aHUS community met with the FDA to talk to them about living with aHUS and…
RDD25: MORE THAN YOU CAN IMAGINE!
Thank You to all Participants! View the completed Rare Disease Day 2024 project here http://bit.ly/RDday2025aHUS The background to the video is…
Is a patient organisation still needed for aHUS?
As another year turns in the aHUS world it is perhaps a time to reflect once more on the mission of…
Eculizumab biosimilars available in Europe and USA
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
aHUS is likely at any time of year
More data about the time of year for aHUS was collected in the recent aHUS Global Poll to add to that…
What’s New in aHUS Research: SEPT 2024 Edition
Every year since the first aHUS Awareness Day on 24 Sept 2015 we’ve attempted to shine a spotlight on atypical HUS…
- 1
- 2
- 3
- 4
- …
- 24
- Go to the next page